Literature DB >> 16530523

Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats.

Martin Hennenberg1, Erwin Biecker, Jonel Trebicka, Kerstin Jochem, Qi Zhou, Martina Schmidt, Karl H Jakobs, Tilman Sauerbruch, Jörg Heller.   

Abstract

BACKGROUND & AIMS: Portal hypertension is associated with arterial hypotension and vascular hypocontractility, which persists despite elevated plasma levels of vasoconstrictors. We investigated the role of the RhoA/Rho-kinase pathway in vascular smooth muscle hypocontractility of rats with secondary biliary cirrhosis.
METHODS: Aortic expressions of RhoA and Rho-kinase were analyzed in sham-operated and BDL rats by reverse-transcription polymerase chain reaction (RT-PCR) and immunoblots. Activation of aortic RhoA was examined by pull down of guanosine triphosphate (GTP)-RhoA and membrane translocation of RhoA. Rho-kinase activity was assessed as phosphorylation of its substrate, moesin. Contractility of isolated aortic rings was determined myographically. The hemodynamic effect of the Rho-kinase inhibitor (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide (Y-27632) was determined in vivo by measuring changes in mean arterial pressure and systemic vascular resistance (SVR) (microspheres).
RESULTS: Contraction of aortic rings from BDL rats was impaired in response to the alpha(1)-adrenergic receptor agonist methoxamine but not to high molar KCl. Aortic expression of RhoA was unchanged in cirrhotic rats, whereas Rho-kinase was down-regulated posttranscriptionally. Methoxamine-induced activation of RhoA as well as basal and methoxamine-induced phosphorylation of moesin were strongly reduced in aortas from cirrhotic rats. Aortic rings from cirrhotic rats precontracted with methoxamine showed an increased sensitivity to relaxation with Y-27632. The drop in SVR induced by Y-27632 was larger in cirrhotic rats than in sham-operated rats.
CONCLUSIONS: An impaired vascular activation of RhoA and a down-regulation of Rho-kinase might contribute to vasodilation and vascular hypocontractility in BDL-induced cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530523     DOI: 10.1053/j.gastro.2005.11.029

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha.

Authors:  Seema S Desai; Jason C Tung; Vivian X Zhou; James P Grenert; Yann Malato; Milad Rezvani; Regina Español-Suñer; Holger Willenbring; Valerie M Weaver; Tammy T Chang
Journal:  Hepatology       Date:  2016-03-09       Impact factor: 17.425

2.  Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.

Authors:  Jiqiao Liu; Liping Peng; Juan Yang; Min Wang; Shengnan Xu; Jingmei Liu; Ping Han; Jiayi He; Dean Tian; Qi Zhou
Journal:  Dig Dis Sci       Date:  2015-02-28       Impact factor: 3.199

Review 3.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

4.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice.

Authors:  Kai Y Mak; Ruth Chin; Sharon C Cunningham; Miriam R Habib; Joseph Torresi; Alexandra F Sharland; Ian E Alexander; Peter W Angus; Chandana B Herath
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 5.  New cellular and molecular targets for the treatment of portal hypertension.

Authors:  Jordi Gracia-Sancho; Raquel Maeso-Díaz; Anabel Fernández-Iglesias; María Navarro-Zornoza; Jaime Bosch
Journal:  Hepatol Int       Date:  2015-03-05       Impact factor: 6.047

6.  Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension.

Authors:  Min Shi; Jue Wei; Wen-Ying Meng; Na Wang; Ting Wang; Yu-Gang Wang
Journal:  Exp Ther Med       Date:  2016-06-14       Impact factor: 2.447

7.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

8.  Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury.

Authors:  Jai Prakash; Martin H de Borst; Marie Lacombe; Frank Opdam; Pieter A Klok; Harry van Goor; Dirk K F Meijer; Frits Moolenaar; Klaas Poelstra; Robbert J Kok
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

9.  Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.

Authors:  M Hennenberg; J Trebicka; C Stark; A Z Kohistani; J Heller; T Sauerbruch
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

10.  Estrogen improves the hyperdynamic circulation and hyporeactivity of mesenteric arteries by alleviating oxidative stress in partial portal vein ligated rats.

Authors:  Bin Zhang; Cheng-Gang Zhang; Quan-Bo Zhou; Wei Chen; Zhi-Yong Wu
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.